Cryo-Cell International Inc. (CCEL) Co-CEO gets new 200,000 option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cryo-Cell International Inc. director, Chairman and Co-CEO David Portnoy reported updated holdings and new equity awards. On January 7, 2026, he was granted two direct stock option awards: one for 50,000 shares and another for 150,000 shares of common stock, both with an exercise price of $3.89 per share and expirations in 2031.
The 50,000 options vest in three equal parts: upon grant, on January 7, 2027, and on January 7, 2028. The 150,000 options, granted under the Cryo-Cell 2022 Stock Incentive Plan, are split into three equal tranches that each require both time-based service and stock-price performance hurdles of $6, $8, and $10 per share, each measured over 20 consecutive trading days after the first, second, and third anniversaries of grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
19 transactions reported
Mixed
19 txns
Insider
PORTNOY DAVID
Role
Chairman, Co-CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 50,000 | $3.89 | $195K |
| Grant/Award | Stock Option | 150,000 | $3.89 | $584K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 50,000 shares (Direct);
Common Stock — 161,833 shares (Indirect, By Corporation);
Common Stock — 847,629 shares (Direct)
Footnotes (1)
- Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary. Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary. Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership. Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027. Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028. The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.
FAQ
What insider activity did Cryo-Cell International (CCEL) report for David Portnoy?
The filing shows that David Portnoy, a director, Chairman and Co-CEO and 10% owner of Cryo-Cell International, received new stock option grants on January 7, 2026 and reported his updated direct and indirect common stock and option holdings.
How many new stock options did David Portnoy receive in the latest CCEL Form 4?
David Portnoy received two new direct stock option grants: one for 50,000 shares and one for 150,000 shares of Cryo-Cell common stock, each with an exercise price of $3.89 per share.
What are the vesting terms for David Portnoy’s 50,000 Cryo-Cell stock options granted on January 7, 2026?
The 50,000 stock options granted on January 7, 2026 vest in three equal installments: one-third upon issuance, one-third on January 7, 2027, and one-third on January 7, 2028.
How do the performance-based vesting conditions work for the 150,000 Cryo-Cell stock options?
The 150,000 options, granted under the Cryo-Cell 2022 Stock Incentive Plan, are split into three equal tranches. Each tranche vests after the first, second, and third anniversaries of the grant date, respectively, and only if the common stock achieves an average closing price of at least $6, $8, or $10 per share, as applicable, over 20 consecutive trading days, subject to Portnoy’s continued service.
What other equity holdings does David Portnoy report in Cryo-Cell International stock?
David Portnoy reports direct ownership of 847,629 shares of Cryo-Cell common stock and additional indirect holdings through entities such as corporations, an LLC, retirement accounts, his spouse, and custodial accounts for his sons, as well as multiple existing stock option positions with various exercise prices and expirations.
Are David Portnoy’s Cryo-Cell stock options subject to stock price targets?
Yes. One existing option grant will vest immediately if the stock price reaches $25.00 per share during its seven-year term, and the new 150,000-share grant requires average closing prices of at least $6, $8, and $10 per share over 20 consecutive trading days for each respective tranche to vest.